Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes and weight drug work as well in south asian patients?

NCT ID NCT07809568

Disease control Sponsor: Universiti Sains Malaysia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are observing how tirzepatide works in routine care for adults in Pakistan who have obesity, prediabetes, or type 2 diabetes. The study follows 330 people starting the medicine as part of their normal treatment at ten diabetes and endocrinology centres. Doctors decide the dose and duration, and the study records changes in blood sugar, weight, blood pressure, cholesterol, side effects, and quality of life over 24 weeks. The goal is to understand how the drug performs in a South Asian population where data are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide, a dual GIP/GLP-1 receptor agonist medicine given as an injection
What this could lead to
If tirzepatide performs well in this population, doctors in Pakistan and similar South Asian settings could have clearer guidance on how well it controls blood sugar and weight in everyday practice.
What could go wrong
This is an observational study, so it cannot prove cause and effect, and results may not apply to other groups. People may stop treatment or miss visits, and side effects such as nausea and stomach upset are common with this drug class.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 330 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 years or older with obesity (BMI ≥ 30) who are initiating tirzepatide as part of routine clinical care at ten diabetes and endocrinology centres in Pakistan. Participants are grouped into three cohorts by glycaemic status at entry: obesity without diabetes (HbA1c \< 5.7%), prediabetes with obesity (HbA1c 5.7-6.4%), and type 2 diabetes with obesity (diagnosed at least 6 months prior).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult aged 18 years or older * Obesity (BMI ≥ 30) meeting one cohort definition * Baseline HbA1c available to confirm cohort * Initiating tirzepatide as part of routine clinical care, decided independently of the study * No prior lifetime use of tirzepatide * Washout of at least 8 weeks from any GLP-1 or dual GIP/GLP-1 receptor agonist, if previously used * Baseline retinal (eye) screening completed * Able and willing to provide written informed consent Exclusion Criteria: * Type 1 or secondary diabetes * Any prior tirzepatide use * Proliferative diabetic retinopathy or clinically significant macular oedema * Pregnancy or breastfeeding * Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) * Active malignancy, or a major cardiovascular event within the past 3 months * Inability to undergo retinal assessment * Mental incapacity or language barrier preventing informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity & overweight Obesity type 2 diabetes mellitus Prediabetes or overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aga Khan University Hospital (AKUH)

    Karachi, Sindh, Pakistan

  • Bolan Medical Complex

    Quetta, Balouchistan, Pakistan

  • Capital Development Authority (CDA) Hospital

    Islamabad, Punjab Province, Pakistan

  • Chandka Medical College

    Lārkāna, Sindh, Pakistan

  • Hanif Medical Complex

    Rawalpindi, Punjab Province, Pakistan

  • Indus Hospital Health Network

    Karachi, Sindh, Pakistan

  • Jinnah Postgraduate Medical Centre

    Lahore, Punjab Province, Pakistan

  • Khyber Medical University

    Peshawar, KPK, Pakistan

  • OMI Hospital

    Karachi, Sindh, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.